A differentiated model for clinical-stage value creation
Banyan BioInnovations forms and develops asset-centric NewCos designed to reach defined clinical and regulatory value inflection points — with discipline, capital efficiency, and institutional governance.
Structured company creation · Centralized development execution · Global sourcing advantage
Who We Are
Banyan BioInnovations is an investment firm powered by Locust Walk that leverages global sourcing and on-the-ground presence in the U.S., China and Japan to create clinical-stage companies around best or first-in-class drug candidates. We deploy a veteran centralized development team and turnkey infrastructure to optimize clinical and regulatory execution, guiding each asset through key value inflection points. Banyan Bio’s differentiated and collaborative approach ensures that the drug’s originator, investors, our NewCos, and patients all win together.
“Banyan Bio provides investors with a new model for funding the development of promising clinical-stage drug assets through clear value inflection points. Each Banyan Bio NewCo has a clear clinical objective to create asset value, disciplined and broad capitalization from launch, and access to world-class operational infrastructure. This repeatable operating system aligns each NewCo and its investors with asset originators, enabling a win-win scenario for all parties.”
Why Banyan Bio
Built for execution, alignment, and repeatability
Banyan Bio was designed to address the core challenge in clinical-stage development: translating strong science into credible, well-executed programs that can withstand regulatory scrutiny and attract long-term partners.
Discipline at formation:
Each NewCo is structured from inception with clear governance, defined objectives, and capital discipline — avoiding the inefficiencies common in early-stage development.
Global access with local trust:
Through Locust Walk’s established presence in the U.S., China, and Japan, Banyan Bio engages innovators early and from the advisor side of the table, enabling access others don’t have.
Execution where it matters most:
Clinical strategy, regulatory planning, CMC, and operations are centralized under an experienced team with a proven track record advancing assets globally.
Shared success for originators:
We structure NewCos to ensure that original stakeholders retain meaningful upside and remain incentivized and aligned as we reach clinical milestones.
Strategic Partnerships
We are proud to be launching with a $100M+ commitment from life science investors. ICON plc, a world-leading clinical research organization, is participating through a strategic collaboration and investment. The partnership reflects a shared belief that close collaboration between sponsors and CROs can meaningfully improve the execution and efficiency of clinical development.
How We Create Value
A repeatable approach to clinical execution
Banyan Bio applies a disciplined, repeatable process to every program — from sourcing through value inflection. Each step is designed to reduce risk, preserve optionality, and deliver credible outcomes for all stakeholders.
i
Source & evaluate
Clinical-stage programs with clear regulatory paths, strong data, and compelling scientific rationale
ii
Build the NewCo
Clean structure, aligned incentives, defined milestones
iii
Validate & fund
Through disciplined syndication and independent co-leads
iv
Execute to inflection
Using Banyan Bio’s centralized development platform
We move forward only when the structure, plan, and partnerships are right.
Partnering with Banyan Bio
Banyan Bio partners with biotech, pharma, and academic teams to advance high-quality clinical-stage programs with discipline and resources.
The Ideal Asset
Banyan Bio focuses on clinical-stage programs with:
Clear clinical validation: Patient efficacy data in hand or a well-defined path to early proof-of-concept.
Defined regulatory pathway: A credible FDA or global regulatory strategy, with biomarker-driven endpoints where applicable.
Differentiated mechanism or indication: Best-in-class or first-in-class potential.
Structural fit: Non-core pharma assets, programs needing U.S. regulatory structuring, or development-stage biotechs seeking a strategic execution partner.
What Originators Gain
Shared upside: Retain meaningful participation and long-term value.
Specialized focus: 100% attention from a veteran centralized development team.
Global reach: U.S.-grade clinical/regulatory execution with global business development expertise.
Capital formation expertise: Access to sophisticated financing and investor syndication.
Execution without friction: NewCo operational responsibility handled by Banyan Bio, minimizing internal burden.
Whether advancing a non-core asset or seeking a credentialed partner, Banyan Bio provides a structured path to value.
Our Team
Seasoned executives, proven results
Banyan Bio is led by seasoned executives with decades of experience advancing assets through late-stage development and global regulatory approval. Launching with more than 50 team members at inception, Banyan Bio's team spans drug development, regulatory affairs, CMC, clinical operations, and dealmaking — with on-the-ground presence across the U.S., China, and Japan.
Geoff Meyerson
Co-founder & CEO
Geoff Meyerson is a Co-founder of Banyan BioInnovations and serves as CEO. He is also the founder and CEO of Locust Walk, a global life sciences investment bank that powers Banyan Bio’s sourcing platform. Over the course of his career, Geoff has advised on hundreds of transactions across biotech, pharma, and medtech, with particular depth in cross-border deal structures and clinical-stage asset financing. His relationships across the U.S., China, and Japan form the foundation of Banyan’s global sourcing advantage. Geoff’s work at Locust Walk gives Banyan continuous visibility into clinical-stage programs that are not yet broadly shopped, creating a differentiated and proprietary deal flow engine.
Barbara White
Co-founder & President
Barbara White is a Co-founder of Banyan BioInnovations and serves as President. She brings decades of pharmaceutical development leadership to the organization, including her tenure as a senior development executive at SFJ Pharma, where she oversaw the advancement of multiple assets through late-stage global development and regulatory approval across the U.S., Europe, and Asia. Her experience spans clinical operations, regulatory strategy, CMC, and trial design—the core disciplines that determine whether a clinical-stage program succeeds or fails. Barbara’s hands-on leadership of Banyan Bio’s centralized development platform ensures that every NewCo launches with the infrastructure and expertise needed to execute from day one.
Get In Touch
Let's build something together
Whether you are advancing a promising clinical-stage asset, exploring partnership pathways, or seeking a disciplined platform for company creation, Banyan Bio brings structure, execution rigor, and global perspective to every program.